The Role of Serial Right Heart Catheterization Survey in Patients Awaiting Heart Transplant on Ventricular Assist Device.


Journal

ASAIO journal (American Society for Artificial Internal Organs : 1992)
ISSN: 1538-943X
Titre abrégé: ASAIO J
Pays: United States
ID NLM: 9204109

Informations de publication

Date de publication:
01 05 2022
Historique:
pubmed: 6 8 2021
medline: 6 5 2022
entrez: 5 8 2021
Statut: ppublish

Résumé

Current guidelines recommend serial right heart catheterization (RHC) to survey pulmonary hypertension in patients awaiting heart transplant. However, the role and impact of this surveillance is unclear in patients with a left ventricular assist device (LVAD). We reviewed our surveillance RHC protocol to determine whether useful data were obtained to justify the risks of serial invasive procedures (i.e., excessive bleeding). Between January 2015 and December 2018, 78 patients who received an LVAD as bridge-to-transplant (BTT) were included in this study. Routine RHC surveillance was performed every 6 months. Hemodynamic variables were retrospectively collected and reviewed. In 78 patients, 205 RHCs were analyzed. Median patient age was 54 years (IQR 46-61), and 64 (82%) were male. Thirty-six patients (46%) had pulmonary vascular resistance (PVR) ≤ 3 Wood units (WUs), and 42 patients (54%) had PVR > 3 WUs before LVAD. After LVAD implantation, mean PVR decreased by 36% from 3.8 ± 2.1 to 2.4 ± 1.1 WUs (p < 0.001) at 6 months and stabilized below 3 WUs at all post-LVAD time points. Four patients (11%) with pre-LVAD PVR ≤ 3 and 16 patients (38%) with a pre-LVAD PVR > 3 had PVR > 3 at least once during RHC survey. Of the 56 (76%) transplanted patients, six (40%) of 15 patients with a post-LVAD PVR >3 at least once developed moderate-to-severe right ventricular dysfunction. Although PVR significantly decreased after LVAD implant, PVR values fluctuated, particularly for those with pre-LVAD PVR > 3.0 WUs. Routine RHC appears valid for all BTT patients.

Identifiants

pubmed: 34352817
doi: 10.1097/MAT.0000000000001542
pii: 00002480-202205000-00008
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

663-668

Informations de copyright

Copyright © ASAIO 2021.

Déclaration de conflit d'intérêts

Disclosure: The authors have no conflicts of interest to report.

Références

Matsuda H, Ichikawa H, Ueno T, Sawa Y: Heart transplantation for adults with congenital heart disease: Current status and future prospects. Gen Thorac Cardiovasc Surg 65: 309–320, 2017.
Bhama JK, Shulman J, Bermudez CA, et al.: Heart transplantation for adults with congenital heart disease: Results in the modern era. J Heart Lung Transplant 32:499–504, 2013.
MacGowan GA, Crossland DS, Hasan A, Schueler S: Considerations for patients awaiting heart transplantation-Insights from the UK experience. J Thorac Dis 7: 527–531, 2015.
Cai J, Terasaki PI: Heart transplantation in the United States 2004. Clin Transpl 2004:331–344.
Lundgren J, Söderlund C, Rådegran G: Impact of postoperative pulmonary hypertension on outcome after heart transplantation. Scand Cardiovasc J 51: 172–181, 2017.
Galiè N, Humbert M, Vachiery JL: 2015 ESC/ERS guidelines for the diagnosis and treatment of pulmonary hypertension. Eur Heart J 46: 903–975, 2015.
Strange G, Playford D, Stewart S, et al.: Pulmonary hypertension: Prevalence and mortality in the Armadale echocardiography cohort. Heart 98: 1805–1811, 2012.
Bossone E, D’Andrea A, D’Alto M, et al.: Echocardiography in pulmonary arterial hypertension: From diagnosis to prognosis. J Am Soc Echocardiogr 26: 1–14, 2013.
Haddad F, Hunt SA, Rosenthal DN, Murphy DJ: Right ventricular function in cardiovascular disease, part I: Anatomy, physiology, aging, and functional assessment of the right ventricle. Circulation 117: 1436–1448, 2008.
Lafitte S, Pillois X, Reant P, et al.: Estimation of pulmonary pressures and diagnosis of pulmonary hypertension by Doppler echocardiography: A retrospective comparison of routine echocardiography and invasive hemodynamics. J Am Soc Echocardiogr 26: 457–463, 2013.
Mehra MR, Canter CE, Hannan MM, et al.; International Society for Heart Lung Transplantation (ISHLT) Infectious Diseases, Pediatric and Heart Failure and Transplantation Councils: The 2016 International Society for Heart Lung Transplantation listing criteria for heart transplantation: A 10-year update. J Heart Lung Transplant 35: 1–23, 2016.
Mikus E, Stepanenko A, Krabatsch T, et al.: Reversibility of fixed pulmonary hypertension in left ventricular assist device support recipients. Eur J Cardiothorac Surg 40: 971–977, 2011.
Liden H, Haraldsson A, Ricksten SE, Kjellman U, Wiklund L: Does pretransplant left ventricular assist device therapy improve results after heart transplantation in patients with elevated pulmonary vascular resistance? Eur J Cardiothorac Surg 35: 1029–1034; discussion 1034, 2009.
Ammirati E, Oliva F, Cannata A, et al.: Current indications for heart transplantation and left ventricular assist device: A practical point of view. Eur J Intern Med 25: 422–429, 2014.
Ammirati E, Oliva F, Colombo T, et al.: [Proposal for updated listing criteria for heart transplantation and indications to implant of left ventricular assist devices]. G Ital Cardiol (Rome) 14: 110–119, 2013.
Urban M, Pirk J, Szarszoi O, Besik J, Netuka I: Post-heart transplantation outcome of HeartMate II-bridged recipients requiring unplanned concomitant temporary right ventricular mechanical support. Interact Cardiovasc Thorac Surg 20: 372–378, 2015.
Yoshioka D, Li B, Takayama H, et al.: Outcome of heart transplantation after bridge-to-transplant strategy using various mechanical circulatory support devices. Interact Cardiovasc Thorac Surg 25: 918–924, 2017.
Truby LK, Garan AR, Givens RC, et al.: Ventricular assist device utilization in heart transplant candidates: Nationwide variability and impact on waitlist outcomes. Circ Heart Fail 11: e004586, 2018.
Takeda K, Takayama H, Kalesan B, et al.: Outcome of cardiac transplantation in patients requiring prolonged continuous-flow left ventricular assist device support. J Heart Lung Transplant 34: 89–99, 2015.
Saidi A, Selzman CH, Ahmadjee A, et al.: Favorable effects on pulmonary vascular hemodynamics with continuous-flow left ventricular assist devices are sustained 5 years after heart transplantation. ASAIO J 64: 38–42, 2018.
Uriel N, Imamura T, Sayer G, et al.; Heartmate II Clinical Investigators: High transpulmonary artery gradient obtained at the time of left ventricular assist device implantation negatively affects survival after cardiac transplantation. J Card Fail 25: 777–784, 2019.
Rosenkranz S, Preston IR: Right heart catheterisation: Best practice and pitfalls in pulmonary hypertension. Eur Respir Rev 24: 642–652, 2015.
D’Alto M, Dimopoulos K, Coghlan JG, Kovacs G, Rosenkranz S, Naeije R: Right heart catheterization for the diagnosis of pulmonary hypertension: Controversies and practical issues. Heart Fail Clin 14: 467–477, 2018.
Al-Kindi SG, Farhoud M, Zacharias M, et al.: Left ventricular assist devices or inotropes for decreasing pulmonary vascular resistance in patients with pulmonary hypertension listed for heart transplantation. J Card Fail 23: 209–215, 2017.
Houston BA, Kalathiya RJ, Stevens GR, Russell SD, Tedford RJ: One-and-done: Do left ventricular assist device patients on the transplant list really need frequent right heart catheterization assessments for pulmonary hypertension? J Heart Lung Transplant 34: 1637–1639, 2015.
Kwan WC, Shavelle DM, David R: LaughrunPulmonary vascular resistance index: Getting the units right and why it matters. Clin Cardiol;42: 334–338, 2019.

Auteurs

Diana T Ruan (DT)

From the Columbia University Vagelos College of Physician and Surgeons, New York, New York.

Maryjane Farr (M)

Division of Cardiology, Department of Medicine, Columbia University Medical Center-New York Presbyterian Hospital, New York, New York.

Yuming Ning (Y)

Center for Innovation and Outcomes Research, Department of Surgery, Columbia University Medical Center-New York Presbyterian Hospital, New York, New York.

Paul Kurlansky (P)

From the Columbia University Vagelos College of Physician and Surgeons, New York, New York.
Division of Cardiology, Department of Medicine, Columbia University Medical Center-New York Presbyterian Hospital, New York, New York.
Division of Cardiothoracic Surgery Hospital, Department of Surgery, Columbia University Medical Center-New York Presbyterian Hospital, New York, New York.
Division of Cardiology, Department of Medicine, Columbia University Medical Center-New York Presbyterian Hospital, New York, New York.
Center for Innovation and Outcomes Research, Department of Surgery, Columbia University Medical Center-New York Presbyterian Hospital, New York, New York.

Gabriel Sayer (G)

Division of Cardiology, Department of Medicine, Columbia University Medical Center-New York Presbyterian Hospital, New York, New York.

Nir Uriel (N)

Division of Cardiology, Department of Medicine, Columbia University Medical Center-New York Presbyterian Hospital, New York, New York.

Yoshifumi Naka (Y)

From the Columbia University Vagelos College of Physician and Surgeons, New York, New York.
Division of Cardiology, Department of Medicine, Columbia University Medical Center-New York Presbyterian Hospital, New York, New York.
Division of Cardiothoracic Surgery Hospital, Department of Surgery, Columbia University Medical Center-New York Presbyterian Hospital, New York, New York.
Division of Cardiology, Department of Medicine, Columbia University Medical Center-New York Presbyterian Hospital, New York, New York.
Center for Innovation and Outcomes Research, Department of Surgery, Columbia University Medical Center-New York Presbyterian Hospital, New York, New York.

Koji Takeda (K)

From the Columbia University Vagelos College of Physician and Surgeons, New York, New York.
Division of Cardiology, Department of Medicine, Columbia University Medical Center-New York Presbyterian Hospital, New York, New York.
Division of Cardiothoracic Surgery Hospital, Department of Surgery, Columbia University Medical Center-New York Presbyterian Hospital, New York, New York.
Division of Cardiology, Department of Medicine, Columbia University Medical Center-New York Presbyterian Hospital, New York, New York.
Center for Innovation and Outcomes Research, Department of Surgery, Columbia University Medical Center-New York Presbyterian Hospital, New York, New York.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH